Retraction
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
Paper Information
Record ID:
47298
Author(s):
Publication Date:
September 06, 2022
Retraction Date:
June 28, 2023
(2.4 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- General Surgery Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China
- Gynaecology and Obstetrics Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China
- Gastroenterology Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China
Country:
🇨🇳 ChinaArticle Type:
Publisher:
Hindawi
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (3)
3
Total Citations1
Post-Retraction(33.3%)
1
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
0
Within 1 year
0
After 2+ years
366
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance
Lili Cai, Lan Qu, Yanjie Cheng et al. (6 authors)
Anti-Cancer Drugs
Published: Jun 2024
1 citation
1 citation
366 days after retraction
Retracted: Clinical Study of Anti‐PD‐1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
Computational and Mathematical Methods in Medicine
Computational and Mathematical Methods in Medicine
Open Access
Published: Jan 2023
178 days before retraction
Quick Stats
Total Citations:
4
Years Since Retraction:
2.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025